Tags

Type your tag names separated by a space and hit enter

Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
Breast Cancer. 2010 Apr; 17(2):118-24.BC

Abstract

BACKGROUND

Triple negative (TN) breast cancer is defined as a subtype that is negative for estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2). To clarify the characteristics of TN breast cancer, surveillance data of the Registration Committee of the Japanese Breast Cancer Society were analyzed.

METHOD

Of 14,748 cases registered in 2004, 11,705 (79.4%) were examined for ER, PgR, and HER2. Of these, the most prevalent (53.8%) was a hormone-responsive subtype with ER positive/PgR positive/HER2 negative, followed by TN subtype (15.5%).

RESULTS

The proportion of postmenopausal patients was relatively high in the TN subtype. This cancer was diagnosed at a slightly advanced stage and with more cases positive for lymph node metastases than other subtypes. Morphologically, the TN subtype was more frequently classified as solid-tubular carcinoma. Mucinous, tubular, or secretary carcinomas were frequently found in the hormone receptor positive/HER2 negative subtype, while squamous cell carcinoma, spindle cell carcinoma, and metaplastic carcinoma with bone/cartilage metaplasia were very frequently found in the TN group. Apocrine carcinoma was also found very frequently in the TN group. Selection of chemotherapy was not based on receptor subtypes, but was determined by the degree of tumor progression.

CONCLUSIONS

Although TN types are similar to basal-like breast tumor, as determined by gene profiling, their diagnosis needs verification by determination of the level of epidermal growth factor receptor or cytokeratin 5/6 expression. TN type should be examined further for immunohistochemical features and analyzed for prognostic details in this cohort.

Authors+Show Affiliations

Member of the Research Group, Japanese Breast Cancer Society, Tokyo, Japan. hiwase@kumamoto-u.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19466512

Citation

Iwase, Hirotaka, et al. "Clinicopathological Analyses of Triple Negative Breast Cancer Using Surveillance Data From the Registration Committee of the Japanese Breast Cancer Society." Breast Cancer (Tokyo, Japan), vol. 17, no. 2, 2010, pp. 118-24.
Iwase H, Kurebayashi J, Tsuda H, et al. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer. 2010;17(2):118-24.
Iwase, H., Kurebayashi, J., Tsuda, H., Ohta, T., Kurosumi, M., Miyamoto, K., Yamamoto, Y., & Iwase, T. (2010). Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer (Tokyo, Japan), 17(2), 118-24. https://doi.org/10.1007/s12282-009-0113-0
Iwase H, et al. Clinicopathological Analyses of Triple Negative Breast Cancer Using Surveillance Data From the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer. 2010;17(2):118-24. PubMed PMID: 19466512.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. AU - Iwase,Hirotaka, AU - Kurebayashi,Junichi, AU - Tsuda,Hitoshi, AU - Ohta,Tomohiko, AU - Kurosumi,Masafumi, AU - Miyamoto,Kazuaki, AU - Yamamoto,Yutaka, AU - Iwase,Takuji, Y1 - 2009/05/23/ PY - 2009/01/15/received PY - 2009/03/10/accepted PY - 2009/5/26/entrez PY - 2009/5/26/pubmed PY - 2010/7/16/medline SP - 118 EP - 24 JF - Breast cancer (Tokyo, Japan) JO - Breast Cancer VL - 17 IS - 2 N2 - BACKGROUND: Triple negative (TN) breast cancer is defined as a subtype that is negative for estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2). To clarify the characteristics of TN breast cancer, surveillance data of the Registration Committee of the Japanese Breast Cancer Society were analyzed. METHOD: Of 14,748 cases registered in 2004, 11,705 (79.4%) were examined for ER, PgR, and HER2. Of these, the most prevalent (53.8%) was a hormone-responsive subtype with ER positive/PgR positive/HER2 negative, followed by TN subtype (15.5%). RESULTS: The proportion of postmenopausal patients was relatively high in the TN subtype. This cancer was diagnosed at a slightly advanced stage and with more cases positive for lymph node metastases than other subtypes. Morphologically, the TN subtype was more frequently classified as solid-tubular carcinoma. Mucinous, tubular, or secretary carcinomas were frequently found in the hormone receptor positive/HER2 negative subtype, while squamous cell carcinoma, spindle cell carcinoma, and metaplastic carcinoma with bone/cartilage metaplasia were very frequently found in the TN group. Apocrine carcinoma was also found very frequently in the TN group. Selection of chemotherapy was not based on receptor subtypes, but was determined by the degree of tumor progression. CONCLUSIONS: Although TN types are similar to basal-like breast tumor, as determined by gene profiling, their diagnosis needs verification by determination of the level of epidermal growth factor receptor or cytokeratin 5/6 expression. TN type should be examined further for immunohistochemical features and analyzed for prognostic details in this cohort. SN - 1880-4233 UR - https://www.unboundmedicine.com/medline/citation/19466512/Clinicopathological_analyses_of_triple_negative_breast_cancer_using_surveillance_data_from_the_Registration_Committee_of_the_Japanese_Breast_Cancer_Society_ L2 - https://dx.doi.org/10.1007/s12282-009-0113-0 DB - PRIME DP - Unbound Medicine ER -